Inflammatory Bowel Diseases
Journal
-
- Overview
-
- Identity
-
- View All
-
Overview
publication venue for
-
The Performance of the Rutgeerts Score, SES-CD, and MM-SES-CD for Prediction of Postoperative Clinical Recurrence in Crohn’s Disease
2023
-
IMPROVING PATIENT PARTICIPATION IN LONGITUDINAL RESEARCH: AN INNOVATIVE PATIENT-LED PATIENT-ORIENTED QUALITATIVE RESEARCH PROJECT TO UNDERSTAND THE MOTIVATIONS AND BARRIERS TO GETTING AND STAYING INVOLVED IN THE IMAGINE SPOR STUDY
2021
-
P047 HISTOLOGICAL AND ENDOSCOPIC HEALING AFTER QBECO TREATMENT IN AN OPEN-LABEL PHASE 2 STUDY IN PATIENTS WITH ULCERATIVE COLITIS
2018
-
Allied Health Professional Support in Pediatric Inflammatory Bowel Disease: A Survey from the Canadian Pediatric IBD Network
2017
-
Early Use of Therapeutic Drug Monitoring to Individualize Infliximab Therapy in Paediatric IBD, a Multicentre Prospective Study
2017
-
Proximal Disease Extension in Limited Ulcerative Colitis: A Systematic Review and Meta-Analysis
2017
-
Mucosal Healing Is Associated with Improved Long-Term Outcomes in Crohn's Disease: A Systematic Review and Meta-analysis
2016
-
Mucosal Healing Is Associated with Improved Long-Term Outcomes in Ulcerative Colitis: A Systematic Review and Meta-analysis
2016
-
P-064 Impact of High Dose Vitamin D3 Supplementation in Treatment of Crohnʼs Disease in Remission
2016
-
P-079 YI The Association Between Anxiety and Depression and Health Related Quality of Life in Patients with Inflammatory Bowel Disease (IBD)
2016
-
P-231 YI Patient Experience Living with Inflammatory Bowel Disease
2016
-
Does Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease Impact Clinical Management? A Canadian Experience.
2012
-
Validation and Comparison of Algorithms to Identify Adult-Onset Inflammatory Bowel Disease Patients From Within Health Administrative Data
2012
-
Evolution of the phenotypic characteristics of pediatric Inflammatory Bowel Disease using the Paris classification
2011
-
Interdisciplinary, prompt access IBD clinic: The hamilton health science experience
2011
-
Exploring the reliability of phenotypic assignment for pediatric inflammatory bowel disease.
2011
-
Severe neutropenia following a single infliximab infusion in a child with Crohn disease
2009
-
Infliximab-induced psoriasis in pediatric Crohn Disease; Experience of this paradoxical event at a tertiary centre
2008
-
Life threatening complications of sulphasalazine therapy in pediatric inflammatory bowel disease
2008
-
Discontinuation of immunomodulator therapy in infliximab-treated children with Crohn disease; one year outcome evaluating influences on disease activity and infliximab antibody formation
2008
-
The Vagus Nerve
2006
-
Comparative Efficacy of Biologics and Small Molecule Therapies in Improving Patient-Reported Outcomes in Ulcerative Colitis: Systematic Review and Network Meta-Analysis.
31:1272-1280.
2025
-
Longitudinal Monitoring of Inflammatory Bowel Disease in Mice Using Endoscopic Optical Coherence Tomography..
izaf045.
2025
-
EXPLORING THE ROLE OF MICROBIAL PHOSPHOLIPIDS IN VISCERAL HYPERSENSITIVITY AND ALTERED EMOTIONAL BEHAVIOUR INDUCED BY INFLAMMATORY BOWEL DISEASE (IBD)-ASSOCIATED MICROBIOTA.
31:S52-S52.
2025
-
FECAL PROTEOLYTIC ACTIVITY AND SYMPTOMATIC STATUS ARE ASSOCIATED IN CROHN’S DISEASE.
31:s16-s17.
2025
-
LYSOPHOSPHATIDYLCHOLINE (LPC) AND LYSOPHOSPHATIDIC ACID (LPA) INDUCE NEURONAL ACTIVATION AND HAVE DIFFERENTIAL EFFECTS ON ENTERIC GLIAL CELLS AND SPLENOCYTES.
31:S55-S55.
2025
-
LYTIC PHAGE ATTENUATES COLITIS SEVERITY IN GNOTOBIOTIC MICE COLONIZED WITH IBD-ASSOCIATEDE. COLI NRG857C.
31:s4-s5.
2025
-
Crohn’s Disease Phenotypes and Associations With Comorbidities, Surgery Risk, Medications and Nonmedication Approaches: The MAGIC in IMAGINE Study.
31:113-122.
2025
-
Landscape of TPMT and NUDT15 Pharmacogenetic Variation in a Cohort of Canadian Pediatric Inflammatory Bowel Disease Patients.
30:2418-2427.
2024
-
Characteristics of Interventional Trials for Patients Living With Intestinal Stoma Registered in ClinicalTrials.gov With a Focus on Inflammatory Bowel Disease.
30:2037-2045.
2024
-
Early Biologic Treatment Decreases Risk of Surgery in Crohn’s Disease but not in Ulcerative Colitis: Systematic Review and Meta-Analysis.
30:1080-1086.
2024
-
Endoscopic and Histological Placebo Rates in Crohn’s Disease Clinical Trials: A Systematic Review and Meta-analysis.
30:651-659.
2024
-
Predicting Endoscopic Improvement in Ulcerative Colitis Using the Ulcerative Colitis Severity Index.
30:370-381.
2024
-
Matching-adjusted Indirect Comparisons vs Propensity Score Matching with Individual Patient-level Data to Estimate Treatment Efficacy.
30:311-313.
2024
-
Histological Remission Placebo Rates in Ulcerative Colitis Trials: A Systematic Review and Meta-analysis.
30:125-131.
2024
-
Inflammatory Bowel Disease Among Canadian Children: Comparison Between Children of Non-European Descent and Children of European Descent.
29:1760-1768.
2023
-
Predictors of Clinical Remission to Placebo in Clinical Trials of Crohn’s Disease.
29:1390-1398.
2023
-
Ulcer Size After Induction Therapy Performs Better Than Symptom Assessment for Prediction of One Year Endoscopic Remission in Crohn’s Disease: A Post Hoc Analysis.
29:1263-1271.
2023
-
Comparative Efficacy of Infliximab vs Ustekinumab for Maintenance of Clinical Response in Biologic Naïve Crohn’s Disease.
29:1015-1023.
2023
-
Increased Expression of Interleukin-13 Receptor in Ileum Associated With Nonresponse to Adalimumab in Ileal Crohn’s Disease.
29:875-882.
2023
-
Comparison of the Relative Sensitivity of Clinical, Endoscopic, and Histologic Remission for Detection of Treatment Efficacy in Ulcerative Colitis Trials.
29:324-327.
2023
-
Decision Support Tool Identifies Ulcerative Colitis Patients Most Likely to Achieve Remission With Vedolizumab vs Adalimumab.
28:1555-1564.
2022
-
Letter to the Editor: Too Soon to Dismiss Inflammation-Related Differences in the Mucosa-Associated Microbiota in Crohn’s Disease Patients.
28:e120-e120.
2022
-
Increased Bacterial Proteolytic Activity Detected Before Diagnosis of Ulcerative Colitis.
27:e144-e144.
2021
-
Medical Management Following Surgical Therapy in Inflammatory Bowel Disease: Evidence from Cochrane Reviews.
27:1513-1524.
2021
-
Body Mass Index Does Not Impact Clinical Efficacy of Ustekinumab in Crohn’s Disease: A Post Hoc Analysis of the IM-UNITI Trial.
27:848-854.
2021
-
Salicylates Ameliorate Intestinal Inflammation by Activating Macrophage AMPK.
27:914-926.
2021
-
Worldwide Management of Inflammatory Bowel Disease During the COVID-19 Pandemic: An International Survey.
27:836-847.
2021
-
Risk of Postoperative Infectious Complications From Medical Therapies in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.
26:1796-1807.
2020
-
Interrogating the Gut-Brain Axis in the Context of Inflammatory Bowel Disease: A Translational Approach.
26:493-501.
2020
-
Age-Related Survival Differences in Patients With Inflammatory Bowel Disease–Associated Colorectal Cancer: A Population-Based Cohort Study.
25:1957-1965.
2019
-
Analysis of Genetic Association of Intestinal Permeability in Healthy First-degree Relatives of Patients with Crohn’s Disease.
25:1796-1804.
2019
-
Response to Letter by Moulton et al..
25:e99-e99.
2019
-
Anxiety But Not Depression Predicts Poor Outcomes in Inflammatory Bowel Disease.
25:1255-1261.
2019
-
Antibiotics Potentiate Adherent-InvasiveE. coliInfection and Expansion.
25:711-721.
2019
-
Appropriateness of Biologics in the Management of Crohn’s Disease Using RAND/UCLA Appropriateness Methodology.
25:328-335.
2019
-
Clinical Practice Guideline for the Medical Management of Perianal Fistulizing Crohn’s Disease: The Toronto Consensus.
25:1-13.
2019
-
The Role of Biomarkers in Clinical Trials of Inflammatory Bowel Disease.
24:1619-1623.
2018
-
Enhanced TH17 Responses in Patients with IL10 Receptor Deficiency and Infantile-onset IBD.
23:1950-1961.
2017
-
Systematic Review and Meta-analysis.
23:1702-1709.
2017
-
Systematic Review and Meta-analysis: Fecal Microbiota Transplantation for Treatment of Active Ulcerative Colitis..
23:1702-1709.
2017
-
Modified Delphi Process for the Development of Choosing Wisely for Inflammatory Bowel Disease.
23:858-865.
2017
-
Trends in Narcotic and Corticosteroid Prescriptions in Patients with Inflammatory Bowel Disease in the United States Ambulatory Care Setting from 2003 to 2011.
23:868-874.
2017
-
Development of the IBD Disk.
23:333-340.
2017
-
Adverse Events During Anti-TNFα Therapies in IBD (Excluding Infections and Malignancies).
22:1239-1245.
2016
-
New Applications for Traditional Drugs in Inflammatory Bowel Disease.
21:2948-2957.
2015
-
Ecobiotherapy Rich in Firmicutes Decreases Susceptibility to Colitis in a Humanized Gnotobiotic Mouse Model.
21:1883-1893.
2015
-
Systematic Review.
21:1683-1694.
2015
-
Anti-TNFα Therapies Are Safe During Pregnancy in Women with Inflammatory Bowel Disease.
20:1862-1869.
2014
-
The Commensal Bacterium Faecalibacterium prausnitzii Is Protective in DNBS-induced Chronic Moderate and Severe Colitis Models.
20:417-430.
2014
-
Hepatotoxicity Caused by Methotrexate Therapy in Children with Inflammatory Bowel Disease.
20:47-59.
2014
-
P-171 Exploring Needs During Transition from Adolescence to Adulthood in Young Adults with Inflammatory Bowel Disease.
19:S94-S95.
2013
-
Reduced Fat Oxidation Rates During Submaximal Exercise in Adolescents with Crohnʼs Disease.
19:2659-2665.
2013
-
The Utility of Screening for Asymptomatic Lower Extremity Deep Venous Thrombosis during Inflammatory Bowel Disease Flares.
19:1053-1058.
2013
-
Fecal Calprotectin More Accurately Reflects Endoscopic Activity of Ulcerative Colitis than the Lichtiger Index, C-reactive Protein, Platelets, Hemoglobin, and Blood Leukocytes.
19:332-341.
2013
-
IL-10R Polymorphisms Are Associated with Very-early-onset Ulcerative Colitis.
19:115-123.
2013
-
Commensal and Probiotic Bacteria Influence Intestinal Barrier Function and Susceptibility to Colitis in Nod1−/−;Nod2−/− Mice.
18:1434-1446.
2012
-
Differences of small intestinal bacteria populations in adults and children with/without celiac disease: Effect of age, gluten diet, and disease.
18:649-656.
2012
-
Adoptive transfer of macrophage from mice with depression-like behavior enhances susceptibility to colitis.
17:1474-1489.
2011
-
Characterization of Escherichia coli isolated from gut biopsies of newly diagnosed patients with inflammatory bowel disease.
17:1451-1463.
2011
-
Practice of gastroenterologists in treating flaring inflammatory bowel disease patients with clostridium difficile.
17:1540-1546.
2011
-
Pediatric modification of the Montreal classification for inflammatory bowel disease.
17:1314-1321.
2011
-
Assessment of knowledge in adolescents with inflammatory bowel disease using a novel transition tool.
17:1131-1137.
2011
-
Enhanced translocation of bacteria across metabolically stressed epithelia is reduced by butyrate..
16:1138-1148.
2010
-
Assessing disease activity in ulcerative colitis.
16:651-656.
2010
-
Effects of mesalamine (5-aminosalicylic acid) on bacterial gene expression.
15:985-996.
2009
-
Are there epidemiological differences between crohnʼs disease and ulcerative colitis?.
14:S1-S1.
2008
-
Intestinal epithelial barrier dysfunction and dendritic cell redistribution during early stages of inflammation in the rat: Role for TLR-2 and -4 blockage.
14:632-644.
2008
-
Characterization of ileal dendritic cell distribution in a rat model of acute and chronic inflammation.
12:457-470.
2006
-
The Vagus Nerve.
12:s22-s22.
2006
-
Functional gastrointestinal disorders and mood disorders in patients with inactive inflammatory bowel disease: Prevalence and impact on health.
12:38-46.
2006
-
Positron Emission Tomography in the Investigation of Pediatric Inflammatory Bowel Disease.
11:733-738.
2005
-
Chemokine Receptor CXCR3 Expression in Inflammatory Bowel Disease.
7:281-286.
2001
-
All Patients with Inflammatory Bowel Disease Should Have Bone Density Assessment: Pro.
7:158-162.
2001
-
Well-Adjusted Children: An Alternate View of Children with Inflammatory Bowel Disease and Functional Gastrointestinal Complaints.
6:1-7.
2000
-
Bone Mineral Metabolism In Pediatric Inflammatory Bowel Disease.
5:192-199.
1999
-
Management of pouchitis - Authors' reply.
4:333-333.
1998
-
Alterations in enteric nerve and smooth-muscle function in inflammatory bowel diseases.
3:38-48.
1997
-
Matrix Modulation Using Fibrogenic Gene Transfer.
3:149-150.
1997
-
“Immune/Non-Immune Cell Interactions in Intestinal Inflammation” Workshop.
3:133-141.
1997
-
“Immune/non-immune cell interactions in intestinal inflammation” workshop.
3:133-141.
1997
has subject area
Identity
International Standard Serial Number (ISSN)
Electronic International Standard Serial Number (EISSN)